CCL20/CCR6 Expression Profile in Pancreatic Cancer

Overview

Journal J Transl Med

Publisher Biomed Central

Specialties Biomedical Engineering
General Medicine

Date 2010 May 13

PMID 20459729

Citations 34

Authors

Claudia Rubie

Vilma Oliveira Frick

Pirus Ghadjar

Mathias Wagner

Henner Grimm

Benjamin Vicinus

Christoph Justinger

Stefan Graeber

Martin K Schilling

Affiliations

Soon will be listed here.

Abstract

Background: CCL20 and its receptor CCR6 have been shown to play a role in the onset, development and metastatic spread of various gastrointestinal malignancies. In this study, the expression profile and clinical significance of the CCL20/CCR6 system in distinct benign, pre-malignant and malignant pancreatic tissues was investigated.

Methods: Using RealTime-PCR, enzyme-linked immunosorbent assay (ELISA), Western Blot and immunohistochemistry, we have analyzed the expression profile of CCL20/CCR6 in resection specimens from patients with chronic pancreatitis (CP) (n = 22), pancreatic cystadenoma (PA) (n = 11) and pancreatic carcinoma (PCA) (n = 25) as well as in the respective matched normal pancreatic tissues.

Results: CCL20 mRNA and protein was weakly expressed in normal pancreatic tissues and CP and PA specimens but significantly up-regulated in PCA (8-fold) as compared to the matched normal tissue (P < 0.05). Moreover, CCL20 mRNA and protein expression was significantly associated with advanced T-category in patients with PCA (P < 0.05). CCR6 mRNA showed a significant up-regulation in all three disease entities as compared to normal tissues (P < 0.05, respectively).

Conclusion: CCL20 and CCR6 were significantly up-regulated in PCA as compared to the normal pancreatic tissue and CCL20 was significantly associated with advanced T-category in PCA patients. This suggests that CCL20 and CCR6 play a role in the development and progression of PCA and may constitute potential targets for novel treatment strategies.

Citing Articles

Progress of CCL20-CCR6 in the airways: a promising new therapeutic target.

Li Y, Geng W, Li C, Wu J, Gao F, Wang Y J Inflamm (Lond). 2024; 21(1):54.

PMID: 39731176 PMC: 11681768. DOI: 10.1186/s12950-024-00427-5.

Prognostic role of chemokine-related genes in acute myeloid leukemia.

Hou Y, Chen Y, Zhang Y, Li M, Chen J PeerJ. 2024; 12:e17862.

PMID: 39135956 PMC: 11318587. DOI: 10.7717/peerj.17862.

The Role of Chemokines in Orchestrating the Immune Response to Pancreatic Ductal Adenocarcinoma.

Lekan A, Weiner L Cancers (Basel). 2024; 16(3).

PMID: 38339310 PMC: 10854906. DOI: 10.3390/cancers16030559.

Laminin 332 expression levels predict clinical outcomes and chemotherapy response in patients with pancreatic adenocarcinoma.

Sari B, Gulbey O, Hamill K Front Cell Dev Biol. 2023; 11:1242706.

PMID: 37779898 PMC: 10540629. DOI: 10.3389/fcell.2023.1242706.

CCR6 as a Potential Target for Therapeutic Antibodies for the Treatment of Inflammatory Diseases.

Gomez-Melero S, Caballero-Villarraso J Antibodies (Basel). 2023; 12(2).

PMID: 37092451 PMC: 10123731. DOI: 10.3390/antib12020030.

References

Howes N, Neoptolemos J . Risk of pancreatic ductal adenocarcinoma in chronic pancreatitis. Gut. 2002; 51(6):765-6. PMC: 1773485. DOI: 10.1136/gut.51.6.765. View

Marchesi F, Monti P, Leone B, Zerbi A, Vecchi A, Piemonti L . Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res. 2004; 64(22):8420-7. DOI: 10.1158/0008-5472.CAN-04-1343. View

Greaves D, Wang W, Dairaghi D, Dieu M, Rossi D, Caux C . CCR6, a CC chemokine receptor that interacts with macrophage inflammatory protein 3alpha and is highly expressed in human dendritic cells. J Exp Med. 1997; 186(6):837-44. PMC: 2199049. DOI: 10.1084/jem.186.6.837. View

Balkwill F . Cancer and the chemokine network. Nat Rev Cancer. 2004; 4(7):540-50. DOI: 10.1038/nrc1388. View

Lowenfels A, Maisonneuve P, Cavallini G, Ammann R, Lankisch P, Andersen J . Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med. 1993; 328(20):1433-7. DOI: 10.1056/NEJM199305203282001. View

Campbell A, Albo D, Kimsey T, White S, Wang T . Macrophage inflammatory protein-3alpha promotes pancreatic cancer cell invasion. J Surg Res. 2005; 123(1):96-101. DOI: 10.1016/j.jss.2004.07.013. View

Matsui T, Akahoshi T, Namai R, Hashimoto A, Kurihara Y, Rana M . Selective recruitment of CCR6-expressing cells by increased production of MIP-3 alpha in rheumatoid arthritis. Clin Exp Immunol. 2001; 125(1):155-61. PMC: 1906097. DOI: 10.1046/j.1365-2249.2001.01542.x. View

Korc M . Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am. 1998; 7(1):25-41. View

Lukacs N, Prosser D, Wiekowski M, Lira S, Cook D . Requirement for the chemokine receptor CCR6 in allergic pulmonary inflammation. J Exp Med. 2001; 194(4):551-5. PMC: 2193496. DOI: 10.1084/jem.194.4.551. View

10.

Kulbe H, Levinson N, Balkwill F, Wilson J . The chemokine network in cancer--much more than directing cell movement. Int J Dev Biol. 2004; 48(5-6):489-96. DOI: 10.1387/ijdb.041814hk. View

11.

Giovannucci E, Michaud D . The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology. 2007; 132(6):2208-25. DOI: 10.1053/j.gastro.2007.03.050. View

12.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun M . Cancer statistics, 2007. CA Cancer J Clin. 2007; 57(1):43-66. DOI: 10.3322/canjclin.57.1.43. View

13.

Shimizu Y, Murata H, Kashii Y, Hirano K, Kunitani H, Higuchi K . CC-chemokine receptor 6 and its ligand macrophage inflammatory protein 3alpha might be involved in the amplification of local necroinflammatory response in the liver. Hepatology. 2001; 34(2):311-9. DOI: 10.1053/jhep.2001.26631. View

14.

Bustin S . Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol. 2000; 25(2):169-93. DOI: 10.1677/jme.0.0250169. View

15.

Abiko Y, Nishimura M, Kusano K, Nakashima K, Okumura K, Arakawa T . Expression of MIP-3alpha/CCL20, a macrophage inflammatory protein in oral squamous cell carcinoma. Arch Oral Biol. 2003; 48(2):171-5. DOI: 10.1016/s0003-9969(02)00167-x. View

16.

Homey B, Dieu-Nosjean M, Wiesenborn A, Massacrier C, Pin J, OLDHAM E . Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol. 2000; 164(12):6621-32. DOI: 10.4049/jimmunol.164.12.6621. View

17.

Ghadjar P, Loddenkemper C, Coupland S, Stroux A, Noutsias M, Thiel E . Chemokine receptor CCR6 expression level and aggressiveness of prostate cancer. J Cancer Res Clin Oncol. 2008; 134(11):1181-9. DOI: 10.1007/s00432-008-0403-5. View

18.

Kimsey T, Campbell A, Albo D, Wilson M, Wang T . Co-localization of macrophage inflammatory protein-3alpha (Mip-3alpha) and its receptor, CCR6, promotes pancreatic cancer cell invasion. Cancer J. 2005; 10(6):374-80. DOI: 10.1097/00130404-200411000-00007. View

19.

Ebrahimi B, Tucker S, Li D, Abbruzzese J, Kurzrock R . Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer. 2004; 101(12):2727-36. DOI: 10.1002/cncr.20672. View

20.

Caux C, Vanbervliet B, Massacrier C, Ait-Yahia S, Vaure C, Chemin K . Regulation of dendritic cell recruitment by chemokines. Transplantation. 2002; 73(1 Suppl):S7-11. DOI: 10.1097/00007890-200201151-00005. View